Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Barcelona
8 recruitingBarcelona, Spain
Showing 1–8 of 8 trials
Recruiting
Phase 1
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled15 locationsNCT07140016
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca400 enrolled204 locationsNCT07291037
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 3
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Amgen154 enrolled128 locationsNCT06430866
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1Phase 2
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament171 enrolled16 locationsNCT06567015